Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (301-310 of 464) with videos related to

Pageof 47
Sort By:
Journal of Crohn'S & Colitis|June 20, 2018
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 StudyBruce E Sands, William J Sandborn, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 3, 2008
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrinBrian G Feagan, Gordon R Greenberg, Gary Wild, et al.
Gastroenterology|June 18, 2013
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.
Gastroenterology|May 27, 2014
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failedBruce E Sands, Brian G Feagan, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis|November 10, 2021
Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled TrialsAhmed Almradi, Rocio Sedano, Malcolm Hogan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 24, 2019
Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction TrialsMarjolijn Duijvestein, Jenny Jeyarajah, Leonardo Guizzetti, et al.
The New England Journal of Medicine|September 12, 2008
A randomized trial of arthroscopic surgery for osteoarthritis of the kneeAlexandra Kirkley, Trevor B Birmingham, Robert B Litchfield, et al.
Gastroenterology|September 8, 2019
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
International Archives of Allergy and Immunology|September 20, 2021
Systematic Review of Outcome Measures Used in Observational Studies of Adults with Eosinophilic EsophagitisAlain M Schoepfer, Camilla Schürmann, Sven Trelle, et al.
Gut|May 4, 2015
Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's diseaseReena Khanna, Guangyong Zou, Geert D'Haens, et al.
Pageof 47

Showing results (301-310 of 464) with videos related to

Sort By:
Pageof 47
Journal of Crohn'S & Colitis|June 20, 2018
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 StudyBruce E Sands, William J Sandborn, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 3, 2008
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrinBrian G Feagan, Gordon R Greenberg, Gary Wild, et al.
Gastroenterology|June 18, 2013
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.
Gastroenterology|May 27, 2014
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failedBruce E Sands, Brian G Feagan, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis|November 10, 2021
Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled TrialsAhmed Almradi, Rocio Sedano, Malcolm Hogan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 24, 2019
Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction TrialsMarjolijn Duijvestein, Jenny Jeyarajah, Leonardo Guizzetti, et al.
The New England Journal of Medicine|September 12, 2008
A randomized trial of arthroscopic surgery for osteoarthritis of the kneeAlexandra Kirkley, Trevor B Birmingham, Robert B Litchfield, et al.
Gastroenterology|September 8, 2019
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
International Archives of Allergy and Immunology|September 20, 2021
Systematic Review of Outcome Measures Used in Observational Studies of Adults with Eosinophilic EsophagitisAlain M Schoepfer, Camilla Schürmann, Sven Trelle, et al.
Gut|May 4, 2015
Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's diseaseReena Khanna, Guangyong Zou, Geert D'Haens, et al.
Pageof 47